A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years

Clinical Therapeutics

Volumn 28, Issue 3, 2006, Pages 340-351

  Goldstein, Jay L ^a   Aisenberg, James ^b   Lanza, Frank ^c   Schwartz, Howard ^d   Sands, George H ^e   Berger, Manuela F ^e   Pan, Sharon ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MIAMI RESEARCH ASSOCIATES   (United States)

^e PFIZER INC   (United States)

Author keywords

COX 2 selective inhibitor; osteoarthritis; rheumatoid arthritis; ulcers; valdecoxib

Indexed keywords

BACTERIUM ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; VALDECOXIB;

ABDOMINAL PAIN; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DUODENUM; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; FEMALE; FLATULENCE; GASTRITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL MUCOSA; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; METHODOLOGY; MULTICENTER STUDY; NAUSEA; NORMAL HUMAN; OSTEOARTHRITIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SEROLOGY; STATISTICAL SIGNIFICANCE; STOMACH; STOMACH EROSION; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT; XEROSTOMIA;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; DUODENAL ULCER; ENDOSCOPY, GASTROINTESTINAL; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NAPROXEN; STOMACH ULCER; SULFONAMIDES;

EID: 33646881032     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.03.007     Document Type: Article

References (39)

1. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update. Arthritis Rheum 43 (2000) 1905-1915
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46 (2002) 328-346
3. Goldstein J.L., Kivitz A.J., Verburg K.M., et al. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 18 (2003) 125-132
4. [published correction appears in N Engl J Med. 1999;341:548]. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal anti inflammatory drugs. N Engl J Med 340 (1999) 1888-1899
5. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: A view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 7 (2000) 115-121
6. Stoltz R.R., Harris S.I., Kuss M.E., et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 97 (2002) 65-71
7. Wilcox C.M., Alexander L.N., Cotsonis G.A., and Clark W.S. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 42 (1997) 990-997
8. Goldstein J.L., Aisenberg J., Lanza F., et al. Valdecoxib, a COX-2 specific inhibitor, is associated with a lower rate of endoscopic gastroduodenal ulcers than naproxen in healthy subjects (aged65-75 y). Gut 53 Suppl 6 (2004) A118-A119
9. Simon L.S., Lanza F.L., Lipsky P.E., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebocontrolled trialsin osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41 (1998) 1591-1602
10. Simon L.S., Weaver A.L., Graham D.Y., et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 282 (1999) 1921-1928
11. Bombardier C., Laine L., Reicin A., et al., VIGOR Study Group. Comparison of upper gastrointesti nal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
12. Laine L., Bombardier C., Hawkey C.J., et al. Stratifying the risk of NSAID-related upper gastrointestinal clini cal events: Results of a double-blind outcomes study in patients with rheumatoidarthritis. Gastroenterology 123 (2002) 1006-1012
13. Schnitzer T.J., Burmester G.R., Mysler E., et al., TARGET Study Group. Comparison of lumiracoxib with na proxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reductionin ulcer complications: Randomised controlled trial. Lancet 364 (2004) 665-674
14. Silverstein F.E., Faich G., Goldstein J.L., et al., Celecoxib Long-term Arthritis Safety Study. Gastrointes tinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: Arandomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
15. Singh G., Fort J.G., Goldstein J.L., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 119 (2006) 255-266
16. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. Arandomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
17. Singh G., and Rosen Ramey D. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 51 (1998) 8-16
18. Crofford L.J., Lipsky P.E., Brooks P., et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 43 (2000) 4-13
19. Kuehl Jr. F.A., and Egan R.W. Prostaglandins, arachidonic acid, and inflammation. Science 210 (1980) 978-984
20. Bensen W., Weaver A., Espinoza L., et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen. Rheumatology, (Oxford) 41 (2002) 1008-1016
21. Makarowski W., Zhao W.W., Bevirt T., and Recker D.P. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, doubleblind,placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 10 (2002) 290-296
22. McKenna F., Borenstein D., Wendt H., et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 30 (2001) 11-18
23. Kivitz A.J., Moskowitz R.W., Woods E., et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 29 (2001) 467-479
24. Emery P., Zeidler H., Kvien T.K., et al. Celecoxib versus diclofenac in longterm management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 354 (1999) 2106-2111
25. Goldstein J.L., Silverstein F.E., Agrawal N.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95 (2000) 1681-1690
26. Goldstein J.L., Eisen G.M., Agrawal N., et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 20 (2004) 527-538
27. Harris S.I., Kuss M., Hubbard R.C., and Goldstein J.L. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 23 (2001) 1422-1428
28. Laine L., Harper S., Simon T., et al., Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, withthat of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117 (1999) 776-783
29. Pavelka K., Recker D.P., and Verburg K.M. Valdecoxib is as effective as diclofenac in the management of rheu matoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a26-week trial. Rheumatology (Oxford) 42 (2003) 1207-1215
30. Kivitz A., Eisen G., Zhao W.W., et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 51 (2002) 530-537
31. Available at:. Jenkins J.K., and Seligman P.J. Analysis and recommendations for agency action regarding non-steroidal anti inflammatory drugs and cardiovascular risk. Accessed (June 20, 2005). http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf
32. International Conference on Harmonisation. Guideline for good clinical practice (2005). http://www.ich.org/MediaServer.jser?@_ID=482@_MODE=GLB
33. Rabeneck L., Wristers K., Goldstein J.L., et al. Reliability, validity, and responsiveness of Severity of Dys pepsia Assessment (SODA) in a randomized clinical trial of a COX-2-specifiic inhibitorand traditional NSAID therapy. Am J Gastroenterol 97 (2002) 32-39
34. Rabeneck L., Cook K.F., Wristers K., et al. SODA (Severity of Dyspepsia Assessment): A new effective outcome measure for dyspepsia-related health. J Clin Epidemiol 54 (2001) 755-765
35. Eisen G.M., Goldstein J.L., Hanna D.B., and Rublee D.A. Meta-analysis: Upper gastrointestinal tolerability of valde coxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther 21 (2005) 591-598
36. (Suppl). Agrawal N., Paperiello B., Zhao W.W., et al. Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoid arthritis patients. Arthritis Rheum 44 (2001) 128
37. Scheiman J.M., Cryer B., Kimmey M.B., et al. A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury. Clin Gastroenterol Hepatol 2 (2004) 290-295
38. Hawkey C.C., Svoboda P., Fiedorowicz-Fabrycy I.F., et al. Gastroduodenal safety and tolerability of lumiracox ib compared with Ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 31 (2004) 1804-1810
39. Hunt R.H., Harper S., Watson D.J., et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 98 (2003) 1725-1733